Greater Noida, October 6th, 2025: Marking a milestone in advanced cancer care, ShardaCareHealthcity, a leading multispecialty hospital in North India, today reinforced its commitment toproviding world-class oncology treatment by announcing the official launch of instate-of-the art High-Dose-Rate (HDR) Brachytherapy Unit. This advanced technology underscores the hospital’s mission to deliver precision-driven, patient-centric cancer care through cutting-edgeinnovation. The unit has beenspearheaded byDr Anil Thakwani, Senior Consultant & Head ofDept., Oncology, ShardaCare HealthCity.
Brachytherapy is a type of internal radiation therapy that places tiny radioactive sources directlyin or near thetumour, delivering targeted radiation with high precision while minimizing harm tosurrounding healthy tissues. HDR Brachytherapy – manufactured byVarian (earlier Nucleotron)- is an advanced internal radiation technique- utilizes a live source ofIridium-192, enablingclinicians to deliver highly localized doses of radiationdirectly within or next to thetumour. Byplacing the source close to thetumour site, this approach minimizes radiation exposure tonearby healthy tissues—offering enhanced safety and effectiveness compared to conventionalExternal Beam Radiotherapy (EBRT) orLinear Accelerator (LINAC) treatments.
*Speaking about the advancement,Dr. Anil Thakwani, Senior Consultant & H.O.D.- Oncology, ShardaCare Healthcity, said:* “The precision of Brachytherapy is a game-changer, especiallyfor gynaecological cancers like cervical cancer – where nearby organs like the bladder andrectum are at risk during traditional radiation therapy. With HDR Brachytherapy, radiation isconfined to the tumour, greatly reducing collateral damage. This approach allows clinicians todeliver the full therapeutic dose while protecting surrounding healthy organs. By deliveringradiation directly to the tumor, thelow-energy Iridium-192 source ensures nearby critical organssuch as the bladder and rectum are spared. This drastically reduces severe complications likecystitis,rectal ulcers, andfistula formation, which are often limiting factors in traditionalradiotherapy. It allows us to offer safer, more effective treatment while improving the patient’squality of life.
*”He added,* “ShardaCare Healthcity has been managing a growing number of cervical cancercases and other malignancies suitable for Brachytherapy, includingendometrial,prostate, andhead and neck cancers.So far, the hospital has performed over 50 procedures usingBrachytherapy.With increasing awareness, many patients are now presenting at more suitableand treatable stages, while cases referred fromAfrican countries often arrive at more advancedstages. The hospital has been successfully using theHDR Brachytherapy unit over the past yearand has performedmultiple complex cases, including cervical and other cancers, with positive clinical outcomes.”
*Commenting on the milestone, Mr. Rishabh Gupta, Managing Director, ShardaCareHealthcity, said:* “Our investment in thelatest technology likeHDR Brachytherapy Unit, reflectsour unwavering commitment to staying at the forefront of medical innovation. At ShardaCareHealthcity, we’re not just acquiring advanced technologies—we’re redefining precision oncologyby combining expertise, compassion, and the best of globalcancer care. Our goal is to ensureevery patient receives treatment that is safer, more accurate, andoutcomes focused.”
